AI Article Synopsis
- Grey matter volume (GMV) loss has been found in patients with non-alcoholic cirrhosis, but the reasons behind this are still unclear, particularly the role of oxidative stress (OS).
- A study with 34 cirrhotic patients and 27 healthy controls used MRI to assess GMV and measured serum malondialdehyde (MDA) levels as a marker of OS.
- Results showed that cirrhotic patients had lower GMV and higher MDA levels compared to healthy controls, indicating a negative correlation between MDA and GMV, which suggests that oxidative damage may contribute to GMV loss in these patients.
Article Abstract
Background: Grey matter volume (GMV) loss has been observed in patients with non-alcoholic cirrhosis, but the underlying mechanisms are unknown. Oxidative stress (OS) is a recognized feature and systemic phenomenon of cirrhosis. However, little is known about whether OS is associated with GMV loss in cirrhosis. This study aimed to assess the relationship between oxidative damage and GMV loss in patients with non-alcoholic cirrhosis.
Methods: Thirty-four patients with non-alcoholic cirrhosis and 27 age- and sex-matched healthy controls were enrolled in this prospective study. All subjects underwent brain magnetic resonance imaging (MRI), and voxel-based morphometry (VBM) was performed to assess normalized global GMV. As an OS marker, serum malondialdehyde (MDA) levels were determined in all subjects. In the patient group, a correlation analysis was used to investigate the relationship between serum MDA levels and normalized global GMV.
Results: Compared with healthy controls, cirrhotic patients displayed a significant decrease in normalized global GMV and a significant increase in serum MDA levels. In the patient group, serum MDA levels were negatively correlated with normalized global GMV adjusted for age, sex and Child-Pugh class.
Conclusions: Increased serum MDA levels were associated with GMV loss in patients with non-alcoholic cirrhosis, suggesting that oxidative damage may be involved in GMV loss observed in cirrhotic patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414766 | PMC |
| http://dx.doi.org/10.21037/qims.2018.12.12 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Metabolic Dysfunction-Associated Fatty Liver Disease on the Prognosis of Patients With Hepatocellular Carcinoma After Radical Resection: A Retrospective Study.
Cureus
December 2024
Diagnostic Radiology, Bolan Medical College Quetta, Quetta, PAK.
Introduction Although metabolic dysfunction-associated fatty liver disease (MAFLD) is becoming more common in individuals with hepatocellular carcinoma (HCC), it is still unknown how this condition relates to postoperative complications of HCC. While hepatitis B/C virus (HBV/HCV) infection and alcohol use are primary risk factors, MAFLD has emerged as a significant contributor to HCC incidence. Understanding the prognostic impact of MAFLD on HCC outcomes, particularly post-radical resection, is essential.
View Article and Find Full Text PDFPrediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus.
Diabetol Metab Syndr
January 2025
Department of Endocrinology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, No. 126 Daoqian Street, Suzhou, 215000, China.
Background: Formerly known as non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD) has now become the most widespread chronic liver disease worldwide. The primary goal of this study is to assess the ability of different indexes (including VAI, TyG, HOMA-IR, BMI, LAP, WHtR, TyG-BMI, TyG-WC, and TyG-WHtR) to predict MASLD in individuals diagnosed with type 2 diabetes mellitus (T2DM), particularly within the Chinese population.
Methods: This cross-sectional study involved 1,742 patients with T2DM, recruited from the Metabolic Management Centers (MMC) at Suzhou Municipal Hospital.
Background And Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) has a global prevalence of 25%. Studies on incident liver and cardiovascular outcomes in lean (Body mass index: BMI < 25 kg/m, or < 23 kg/m for Asians) vs. non-lean individuals with MASLD have reported mixed results.
View Article and Find Full Text PDFHepatobiliary manifestations of inflammatory bowel disease in Saudi Arabia: A retrospective analysis.
Saudi Med J
January 2025
From the Department of Surgery (Aljiffry, Dahal, Baeisa, Alzahrani, Saleem, Alshahrany), from the Department of Medicine (Hijji, Alsahafi, Alghamdi, Mosli), from the Faculty of Medicine (Aljiffry, Daha, Baeisa, Alzahrani, Alshahrany, Hijji, Alsahafi, Saleem, Alghamdi, Mosli), King Abdulaziz University, from the Inflammatory Bowel Disease Research Group (Alsahafi, Mosli), and from the Gastrointestinal Oncology Unit (Saleem, Alghamdi), King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia.
Objectives: To evaluate the features and frequency of hepatobiliary diseases in individuals with Inflammatory bowel disease (IBD).
Methods: This retrospective study included all IBD patients at King Abdulaziz University Hospital in Jeddah, Saudi Arabia. The primary focus was on the prevalence of hepatobiliary diseases, such as primary sclerosing cholangitis (PSC), non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis (AIH), and others.
Activation of SIRT1 by SRT1720 Alleviates Dyslipidemia, Improves Insulin Sensitivity and Exhibits Liver-Protective Effects in Diabetic Rats on a High-Fat Diet: New Insights into the SIRT1/Nrf2/NFκB Signaling Pathway.
Eur J Pharm Sci
January 2025
Department of Biochemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt. Electronic address:
Insulin resistance and diabetes are associated with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) conditions, which are distinguished by metabolic dysfunction, oxidative stress and inflammation. Sirtuin 1 (SIRT1), a NAD-dependent deacetylase, is fundamental in regulating metabolic pathways, reducing inflammation, and improving antioxidant defenses. This is the first study to investigate the effects of SRT1720, a SIRT1 activator, in diabetic rats on a high-fat diet.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!